Fisetin is a flavonoid that selectively induces apoptosis in senescent cells through activation of the p53 pathway and inhibition of pro-survival signaling (notably BCL-2 family proteins), thereby targeting the senolytic pathway. By clearing senescent cells that accumulate with age and contribute to chronic inflammation and tissue dysfunction, fisetin modulates the hallmark aging pathway of cellular senescence. Preclinical evidence demonstrates improvements in healthspan markers including physical function, metabolic parameters, and extended lifespan in rodent models; human evidence remains limited to surrogate biomarkers showing reduced senescent cell burden and improved physical performance in preliminary trials, with larger controlled studies needed to establish lifespan effects in humans.
Fisetin is a flavonoid sold as a dietary supplement and is not FDA-approved as a drug for any indication. It is studied as a senolytic compound.
Fisetin is studied as a senolytic, similar in proposed mechanism to D+Q, and is sometimes discussed as a complementary or alternative approach. Mayo Clinic trials are tracked as they progress.
Published human evidence specific to longevity or senescence-clearance outcomes has not yet met Geroevidence's minimum threshold for a formal evidence tier.
Fisetin has a generally favorable safety profile as a dietary flavonoid; senolytic-specific dosing and long-term human safety data remain limited.
Both are studied as senolytics. D+Q currently has more published human trial data; fisetin's human evidence base remains under editorial review on Geroevidence. See the senolytics profile for comparison.